Inflammatory bowel disease, liver diseases and endothelial function: Is there a linkage?

Journal of Cardiovascular Medicine

Volumn 16, Issue 1, 2015, Pages 11-21

  Ciccone, Marco Matteo ^a   Principi, Mariabeatrice ^a   Ierardi, Enzo ^b   Leo, Alfredo Di ^a   Ricci, Gabriella ^a   Carbonara, Santa ^a   Gesualdo, Michele ^a   Devito, Fiorella ^a   Zito, Annapaola ^a   Cortese, Francesca ^a   Scicchitano, Pietro ^a  

^a UNIVERSITY OF BARI   (Italy)

^b UNIVERSITY OF FOGGIA   (Italy)

Author keywords

Cardiovascular risk; Endothelial function; Hepatitis; Inflammatory bowel diseases; Nonalcoholic fatty liver disease

Indexed keywords

LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLASMINOGEN ACTIVATOR INHIBITOR 1; TISSUE PLASMINOGEN ACTIVATOR; UROKINASE;

ALCOHOL CONSUMPTION; ATHEROGENESIS; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; BLOOD VESSEL WALL; CAPILLARY ENDOTHELIAL CELL; CARDIOVASCULAR RISK; CAROTID ATHEROSCLEROSIS; CHRONIC HEPATITIS; CROHN DISEASE; ECHOGRAPHY; ENDOTHELIAL DYSFUNCTION; ENDOTHELIAL FUNCTION; ENDOTHELIUM; FATTY LIVER; GASTROINTESTINAL TRACT; GENETIC DISORDER; GENOTYPE; HEPATITIS; HUMAN; IMMUNE RESPONSE; INFLAMMATORY BOWEL DISEASE; INFLAMMATORY CELL; INFLAMMATORY DISEASE; LIPID STORAGE; LIPOPROTEIN METABOLISM; LIVER DISEASE; MUCOSAL IMMUNITY; NONALCOHOLIC FATTY LIVER; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; REVIEW; ULCERATIVE COLITIS; VASCULAR RESISTANCE; COMPLICATION; PATHOPHYSIOLOGY; VASCULAR DISEASE;

ATHEROSCLEROSIS; HEPATITIS; HUMANS; INFLAMMATORY BOWEL DISEASES; NON-ALCOHOLIC FATTY LIVER DISEASE; VASCULAR DISEASES;

EID: 84918546218     PISSN: 15582027     EISSN: 15582035     Source Type: Journal    
DOI: 10.2459/JCM.0000000000000149     Document Type: Review

References (115)

1. Theocharidou E, Gossios TD, Giouleme O, Athyros VG, Karagiannis A. Carotid intima-media thickness in patients with inflammatory bowel disease: A systematic review. Angiology 2014; 65:284-293. doi: 10.1177/0003319713477471.
2. Ross R. Atherosclerosis: An inflammatory disease. N Engl J Med 1999; 340:115-126.
3. Michel JB, Delbosc S, Ho-Tin-Noé B, et al. From intraplaque haemorrhages to plaque vulnerability: biological consequences of intraplaque haemorrhages. J Cardiovasc Med (Hagerstown) 2012; 13:628-634.
4. Falk E, Nakano M, Bentzon JF, Finn AV, Virmani R. Update on acute coronary syndromes: the pathologists' view. Eur Heart J 2013; 34:719- 728.
5. Libby P. Inflammation in atherosclerosis. Nature 2002; 420:868-874.
6. Constantinides P. Importance of the endothelium and blood platelets in the pathogenesis of atherosclerosis. Triangle 1976; 15:53-61.
7. Principi M, Mastrolonardo M, Scicchitano P, et al. Endothelial function and cardiovascular risk in active inflammatory bowel diseases. J Crohns Colitis 2013; 7:e427-e433.
8. Ciccone MM, Scicchitano P, Mitacchione G, et al. Is there a correlation between OSAS duration/severity and carotid intima-media thickness? Respir Med 2012; 106:740-746.
9. Ciccone MM, De Pergola G, Porcelli MT, et al. Increased carotid IMT in overweight and obese women affected by Hashimoto's thyroiditis: An adiposity and autoimmune linkage? BMC Cardiovasc Disord 2010; 10:22.
10. CromerWE, Mathis JM, Granger DN, Chaitanya GV, Alexander JS. Role of the endothelium in inflammatory bowel diseases. World J Gas troenterol 2011; 17:578-593.
11. La Franca E, Caruso M, Sansone A, et al. Relationship between inflammatory markers and new cardiovascular events in patients with acute myocardial infarction who underwent primary angioplasty. Glob J Health Sci 2013; 5:48-54.
12. Corrado E, Rizzo M, Aluigi L, et al. Prediction of vascular events in subjects with subclinical atherosclerosis and the metabolic syndrome: the role of markers of inflammation. Int Angiol 2012; 31:219-226.
13. Corrado E, Rizzo M, Coppola G, et al. An update on the role of markers of inflammation in atherosclerosis. J Atheroscler Thromb 2010; 17:1-11.
14. Markos F, Ruane O'Hora T, Noble MI. What is the mechanism of flow mediated arterial dilatation. Clin Exp Pharmacol Physiol 2013; 40:489- 494.
15. Cocks TM, Angus JA, Campbell JH, Campbell GR. Release and properties of endothelium-derived relaxing factor (EDRF) from endothelial cells in culture. J Cell Physiol 1985; 123:310-320.
16. Ciccone MM, Bilianou E, Balbarini A, et al. Task force on: 'Early markers of atherosclerosis: Influence of age and sex'. J Cardiovasc Med (Hagerstown) 2013; 14:757-766.
17. Ciccone MM, Balbarini A, Teresa Porcelli M, et al. Carotid artery intima- media thickness: normal and percentile values in the Italian population (camp study). Eur J Cardiovasc Prev Rehabil 2011; 18:650-655.
18. Touboul PJ, Hennerici MG, Meairs S, et al. Mannheim carotid intima- media thickness consensus (2004-2006). An update on behalf of the Advisory Board of the 3rd and 4th Watching the Risk Symposium, 13th and 15th European Stroke Conferences, Mannheim, Germany, 2004, and Brussels, Belgium, 2006. Cerebrovasc Dis 2007; 23:75-80.
19. Cosnes J, Gower-Rousseau C, Seksik P, Cortot A. Epidemiology and natural history of inflammatory bowel diseases. Gastroenterology 2011; 140:1785-1794.
20. Parkes M, Satsangi J, Jewell D. Contribution of the IL-2 and IL-10 genes to inflammatory bowel disease (IBD) susceptibility. Clin Exp Immunol 1998; 113:28-32.
21. Langhorst J, Cobelens PM, Kavelaars A, et al. Stress-related peripheral neuro endocrine-immune interactions in women with ulcerative colitis. Psychoneuro endocrinology 2007; 32:1086-1096.
22. Langhorst J, Wieder A, Michalsen A, Musial F, Dobos GJ, Rueffer A. Activated innate immune system in irritable bowel syndrome? Gut 2007; 56:1325-1326.
23. Murthy SK, Nguyen GC. Venous thromboembolism in inflammatory bowel disease: An epidemiological review. Am J Gas troenterol 2011; 106:713- 718.
24. Hatoum OA, Binion DG. The vasculature and inflammatory bowel disease: contribution to pathogenesis and clinical pathology. Inflamm Bowel Dis 2005; 11:304-313.
25. Desreumaux P, Huet G, Zerimech F, et al. Acute inflammatory intestinal vascular lesions and in situ abnormalities of the plasminogen activation system in Crohn's disease. Eur J Gastroenterol Hepatol 1999; 11:1113- 1119.
26. Ha C, Magowan S, Accortt NA, Chen J, Stone CD. Risk of arterial thrombotic events in inflammatory bowel disease. Am J Gastroenterol 2009; 104:1445-1451.
27. Erikson U, Fagerberg S, Krause U, Olding L. Angiographic studies in Crohn's disease and ulcerative colitis. Am J Roentgenol Radium Ther Nucl Med 1970; 110:385-392.
28. Brahme F. Mesenteric angiography in regional entero colitis. Radiology 1966; 87:1037-1042.
29. Funayama Y, Sasaki I, Naito H, Fukushima K, Matsuno S, Masuda T. Remodeling of vascular wall in Crohn's disease. Dig Dis Sci 1999; 44:2319-2323.
30. Talbot RW, Heppell J, Dozois RR, Beart RW Jr. Vascular complications of inflammatory bowel disease. Mayo Clin Proc 1986; 61:140-145.
31. Bernstein CN, Blanchard JF, Houston DS, Wajda A. The incidence of deep venous thrombosis and pulmonary embolism among patients with inflammatory bowel disease: A population-based cohort study. Thromb Haemost 2001; 85:430-434.
32. Danese S, Papa A, Saibeni S, Repici A, Malesci A, Vecchi M. Inflammation and coagulation in inflammatory bowel disease: the clot thickens. Am J Gastroenterol 2007; 102:174-186.
33. Koutroubakis IE. Therapy insight: vascular complications in patients with inflammatory bowel disease. Nat Clin Pract Gastroenterol Hepatol 2005; 2:266-272.
34. Oldenburg B, Van Tuyl BA, van der Griend R, Fijnheer R, van Berge Henegouwen GP. Risk factors for thromboembolic complications in inflammatory bowel disease: the role of hyper homocysteinaemia. Dig Dis Sci 2005; 50:235-240.
35. Solem CA, Loftus EV, Tremaine WJ, Sandborn WJ. Venous thromboembolism in inflammatory bowel disease. Am J Gastroenterol 2004; 99:97-101.
36. van Leuven SI, Hezemans R, Levels JH, et al. Enhanced atherogenesis and altered high density lipoprotein in patients with Crohn's disease. J Lipid Res 2007; 48:2640-2646.
37. Danese S, Sgambato A, Papa A, et al. Homocysteine triggers mucosal micro vascular activation in inflammatory bowel disease. Am J Gastroenterol 2005; 100:886-895.
38. Bregenzer N, Hartmann A, Strauch U, Schö lmerich J, Andus T, Bollheimer LC. Increased insulin resistance and beta cell activity in patients with Crohn's disease. Inflamm Bowel Dis 2006; 12:53-56.
39. Papa A, Danese S, Urgesi R, et al. Early atherosclerosis in patients with inflammatory bowel disease. Eur Rev Med Pharmacol Sci 2006; 10: 7-11.
40. Papa A, Santoliquido A, Danese S, et al. Increased carotid intima-media thickness in patients with inflammatory bowel disease. Aliment Pharmacol Ther 2005; 22:839-846.
41. Horowitz S, Binion DG, Nelson VM, et al. Increased arginase activity and endothelial dysfunction in human inflammatory bowel disease. Am J Physiol Gastrointest Liver Physiol 2007; 292:G1323- G1336.
42. Roifman I, Sun YC, Fedwick JP, et al. Evidence of endothelial dysfunction in patients with inflammatory bowel disease. Clin Gastroenterol Hepatol 2009; 7:175-182.
43. Kocaman O, Sahin T, Aygun C, Senturk O, Hulagu S. Endothelial dysfunction in patients with ulcerative colitis. Inflamm Bowel Dis 2006; 12:166-171.
44. Schinzari F, Armuzzi A, De Pascalis B, et al. Tumor necrosis factor-a antagonism improves endothelial dysfunction in patients with Crohn's disease. Clin Pharmacol Ther 2008; 83:70-76.
45. Zanoli L, Cannavò M, Rastelli S, et al. Arterial stiffness is increased in patients with inflammatory bowel disease. J Hypertens 2012; 30:1775- 1781.
46. Dagli N, Poyrazoglu OK, Dagli AF, et al. Is inflammatory bowel disease a risk factor for early atherosclerosis? Angiology 2010; 61:198-204.
47. Maharshak N, Arbel Y, Bornstein NM, et al. Inflammatory bowel disease is not associated with increased intimal media thickening. Am J Gastroenterol 2007; 102:1050-1055.
48. Broide E, Schopan A, Zaretsky M, Kimchi NA, Shapiro M, Scapa E. Intima-media thickness of the common carotid artery is not significantly higher in Crohn's disease patients compared to healthy population. Dig Dis Sci 2011; 56:197-202.
49. Theocharidou E, Gossios TD, Griva T, et al. Is there an association between inflammatory bowel diseases and carotid intima-media thickness? Preliminary data. Angiology 2013. doi: 10.1177/0003319713489876; [Epub ahead of print].
50. Geerling BJ, Badart-Smook A, Stockbrügger RW, Brummer RJ. Comprehensive nutritional status in recently diagnosed patients with inflammatory bowel disease compared with population controls. Eur J Clin Nutr 2000; 54:514-521.
51. Yarur AJ, Deshpande AR, Pechman DM, Tamariz L, Abreu MT, Sussman DA. Inflammatory bowel disease is associated with an increased incidence of cardiovascular events. Am J Gastroenterol 2011; 106: 741-747.
52. Dorn SD, Sandler RS. Inflammatory bowel disease is not a risk factor for cardiovascular disease mortality: results from a systematic review and meta-analysis. Am J Gastroenterol 2007; 102:662-667.
53. Haapamäki J, Roine RP, Turunen U, Färkkilä MA, Arkkila PE. Increased risk for coronary heart disease, asthma, and connective tissue diseases in inflammatory bowel disease. J Crohns Colitis 2011; 5:41-47.
54. Walsh N, Verster A, Rodolph M, Akl EA. WHO guidance on the prevention of viral hepatitis B and C among people who inject drugs. Int J Drug Policy 2014 [Epub ahead of print]. doi: 10.1016/j.drugpo.2014.01. 009.
55. Ott JJ, Stevens GA, Groeger J, Wiersma ST. Global epidemiology of hepatitis B virus infection: new estimates of age-specific HBsAg seroprevalence and endemicity. Vaccine 2012; 30:2212-2219.
56. Poynard T, Yuen MF, Ratziu V, Lai CL. Viral hepatitis C. Lancet 2003; 362:2095-2100.
57. Dienstag JL. Hepatitis B virus infection. N Engl J Med 2008; 359:1486- 1500.
58. Gibellini D, Borderi M, Clò A, et al. HIV-related mechanisms in atherosclerosis and cardiovascular diseases. J Cardiovasc Med (Hagerstown) 2013; 14:780-790.
59. Abraldes JG, Rodríguez-Vilarrupla A, Graupera M, et al. Simvastatin treatment improves liver sinusoidal endothelial dysfunction in CCl4 cirrhotic rats. J Hepatol 2007; 46:1040-1046.
60. Zafra C, Abraldes JG, Turnes J, et al. Simvastatin enhances hepatic nitric oxide production and decreases the hepatic vascular tone in patients with cirrhosis. Gastroenterology 2004; 126:749-755.
61. Alyan O, Kacmaz F, Ozdemir O, et al. Hepatitis C infection is associated with increased coronary artery atherosclerosis defined by modified Reardon severity score system. Circ J 2008; 72:1960-1965.
62. Ishizaka N, Ishizaka Y, Takahashi E, et al. Increased prevalence of carotid atherosclerosis in hepatitis B virus carriers. Circulation 2002; 105:1028- 1030.
63. Ishizaka Y, Ishizaka N, Takahashi E, et al. Association between hepatitis C virus core protein and carotid atherosclerosis. Circ J 2003; 67:26-30.
64. Caliskan Y, Oflaz H, Pusuroglu H, et al. Hepatitis C virus infection in hemodialysis patients is not associated with insulin resistance, inflammation and atherosclerosis. Clin Nephrol 2009; 71:147-157.
65. Sung J, Song YM, Choi YH, Ebrahim S, Davey Smith G. Hepatitis B virus seropositivity and the risk of stroke and myocardial infarction. Stroke 2007; 38:1436-1441.
66. Bilora F, Campagnolo E, Rinaldi R, Rossato A, Arzenton M, Petrobelli F. Carotid and femoral atherosclerosis in chronic hepatitis C: A 5-year follow up. Angiology 2008 December-2009 January;59:717-720.
67. Bilora F, Rinaldi R, Boccioletti V, Petrobelli F, Girolami A. Chronic viral hepatitis: A prospective factor against atherosclerosis. A study with echocolor Doppler of the carotid and femoral arteries. Gastroenterol Clin Biol 2002; 26:1001-1004.
68. Fernández-Rodríguez CM, Ló pez-Serrano P, Alonso S, et al. Long-term reversal of hypocholesterolaemia in patients with chronic hepatitis C is related to sustained viral response and viral genotype. Aliment Pharmacol Ther 2006; 24:507-512.
69. Wisniewska-Ligier M, Wozniakowska-Gesicka T, Kups J, Sulat-Syncerek D. Lipid metabolism in children with chronic hepatitis C. A preliminary report. Hepatogastroenterology 2006; 53:887-891.
70. Dai CY, Chuang WL, Ho CK, et al. Associations between hepatitis C viremia and low serum triglyceride and cholesterol levels: A community based study. J Hepatol 2008; 49:9-16.
71. Marzouk D, Sass J, Bakr I, et al. Metabolic and cardiovascular risk profiles and hepatitis C virus infection in rural Egypt. Gut 2007; 56:1105-1110.
72. Mostafa A, Mohamed MK, Saeed M, et al. Hepatitis C infection and clearance: Impact on atherosclerosis and cardio metabolic risk factors. Gut 2010; 59:1135-1140.
73. Haji SA, Starling RC, Avery RK, et al. Donor hepatitis-C seropositivity is an independent risk factor for the development of accelerated coronary vasculopathy and predicts outcome after cardiac transplantation. J Heart Lung Transplant 2004; 23:277-283.
74. Boddi M, Abbate R, Chellini B, et al. Hepatitis C virus RNA localization in human carotid plaques. J Clin Virol 2010; 47:72-75.
75. Boddi M, Abbate R, Chellini B, et al. HCV infection facilitates asymptomatic carotid atherosclerosis: preliminary report of HCV RNA localization in human carotid plaques. Dig Liver Dis 2007; 39 (Suppl 1):S55-S60.
76. Radkowski M, Gallegos-Orozco JF, Jablonska J, et al. Persistence of hepatitis C virus in patients successfully treated for chronic hepatitis C. Hepatology 2005; 41:106-114.
77. Giannini C, Giannelli F, Zignego AL. Association between mixed cryoglobulinemia, t(4;18) translocation, and persistence of occult HCV lymphatic infection after treatment. Hepatology 2006; 43:1166-1167.
78. Ishizaka N, Ishizaka Y, Takahashi E, et al. Association between hepatitis C virus seropositivity, carotid-artery plaque, and intima-media thickening. Lancet 2002; 359:133-135.
79. Takase B, Uehata A, Fujioka T, et al. Endothelial dysfunction and decreased exercise tolerance in interferon-alpha therapy in chronic hepatitis C: relation between exercise hyperemia and endothelial function. Clin Cardiol 2001; 24:286-290.
80. Uehata A, Takase B, Nag T, et al. Reversible endothelial dysfunction caused by interferon alpha therapy in chronic hepatitis C patients. Circulation 1997; 96:1-7.
81. Fukui M, Kitagawa Y, Nakamura N, Yoshikawa T. Hepatitis C virus and atherosclerosis in patients with type 2 diabetes. J Am Med Assoc 2003; 289:1245-1246.
82. Targher G, Bertolini L, Padovani R, Rodella S, Arcaro G, Day C. Differences and similarities in early atherosclerosis between patients with nonalcoholic steatohepatitis and chronic hepatitis B and C. J Hepatol 2007; 46:1126-1132.
83. Petta S, Torres D, Fazio G, et al. Carotid atherosclerosis and chronic hepatitis C: A prospective study of risk associations. Hepatology 2012; 55:1317-1323.
84. Wang CS, Wang ST, Yao WJ, Chang TT, Chou P. Hepatitis C virus infection and the development of type 2 diabetes in a community-based longitudinal study. Am J Epidemiol 2007; 166:196-203.
85. Petta S, Cammà C, Di Marco V, et al. Insulin resistance and diabetes increase fibrosis in the liver of patients with genotype 1 HCV infection. Am J Gastroenterol 2008; 103:1136-1144.
86. Camma C, Petta S. Insulin resistance in HCV mono-infected and in HIV/HCV co-infected patients: looking to the future. J Hepatol 2009; 50:648- 651.
87. Lonardo A, Adinolfi LE, Petta S, Craxì A, Loria P. Hepatitis C and diabetes: the inevitable coincidence? Expert Rev Anti Infect Ther 2009; 7:293- 308.
88. Petta S, Amato M, Cabibi D, et al. Visceral adiposity index is associated with histological findings and high viral load in patients with chronic hepatitis C due to genotype 1. Hepatology 2010; 52:1543-1552.
89. Chalasani N, Younossi Z, Lavine JE, et al. The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Hepatology 2012; 55:2005-2023.
90. Josef P, Ali I, Ariel P, Alon M, Nimer A. Relationship between retinal vascular caliber and coronary artery disease in patients with non-alcoholic fatty liver disease (NAFLD). Int J Environ Res Public Health 2013; 10:3409-3423.
91. McCullough AJ. The clinical features, diagnosis and natural history of nonalcoholic fatty liver disease. Clin Liver Dis 2004; 8:521-533.
92. Perseghin G, Lattuada G, De Cobelli F, et al. Serum resistin and hepatic fat content in nondiabetic individuals. J Clin Endocrinol Metab 2006; 91:5122-5125.
93. Assy N, Bekirov I, Mejritsky Y, Solomon L, Szvalb S, Hussein O. Association between thrombotic risk factors and extent of fibrosis in patients with nonalcoholic fatty liver diseases. World J Gastroenterol 2005; 11:5834-5839.
94. Marchesini G, Marzocchi R, Agostini F, Bugianesi E. Nonalcoholic fatty liver disease and the metabolic syndrome. Curr Opin Lipidol 2005; 16:421-427.
95. Targher G, Arcaro G. Nonalcoholic fatty liver disease and increased risk of cardiovascular disease. Atherosclerosis 2007; 191:235-240.
96. Akahoshi M, Amasaki Y, Soda M, et al. Correlation between fatty liver and coronary risk factors: A population study of elderly men and women in Nagasaki. Jpn Hypertens Res 2001; 24:337-343.
97. Ikai E, Ishizaki M, Suzuki Y, Ishida M, Noborizaka Y, Yamada Y. Association between hepatic steatosis, insulin resistance and hyperinsulinaemia as related to hypertension in alcohol consumers and obese people. J Hum Hypertens 1995; 9:101-105.
98. Volzke H, Robinson DM, Kleine V, et al. Hepatic steatosis is associated with an increased risk of carotid atherosclerosis. World J Gastroenterol 2005; 11:1848-1853.
99. Kim HC, Kim DJ, Huh KB. Association between nonalcoholic fatty liver disease and carotid intima-media thickness according to the presence of metabolic syndrome. Atherosclerosis 2009; 204:521-525.
100. Sookoian S, Pirola CJ. Nonalcoholic fatty liver disease is strongly associated with carotid atherosclerosis: A systematic review. J Hepatol 2008; 49:600-607.
101. Manco M, BedogniG, Monti L, Morino G, Natali G, Nobili V. Intima-media thickness and liver histology in obese children and adolescents with nonalcoholic fatty liver disease. Atherosclerosis 2010; 209:463- 468.
102. Weghuber D, Roden M, Franz C, et al. Vascular function in obese children with nonalcoholic fatty liver disease. Int J Pediatr Obes 2011; 6:120- 127.
103. Pacifico L, Anania C, Martino F, et al. Functional and morphological vascular changes in pediatric nonalcoholic fatty liver disease. Hepatology 2010; 52:1643-1651.
104. Pacifico L, Arca M, Anania C, Cantisani V, Di Martino M, Chiesa C. Arterial function and structure after a 1-year lifestyle intervention in children with nonalcoholic fatty liver disease. Nutr Metab Cardiovasc Dis 2013; 23:1010-1016.
105. Kucukazman M, Ata N, Yavuz B, et al. Evaluation of early atherosclerosis markers in patients with nonalcoholic fatty liver disease. Eur J Gastroenterol Hepatol 2013; 25:147-151.
106. Thakur ML, Sharma S, Kumar A, et al. Nonalcoholic fatty liver disease is associated with subclinical atherosclerosis independent of obesity and metabolic syndrome in Asian Indians. Atherosclerosis 2012; 223:507- 511.
107. Vlachopoulos C, Manesis E, Baou K, et al. Increased arterial stiffness and impaired endothelial function in nonalcoholic fatty liver disease: A pilot study. Am J Hypertens 2010; 23:1183-1189.
108. Targher G, Pichiri I, Zoppini G, et al. Increased prevalence of cardiovascular disease among type 2 diabetic patients with nonalcoholic fatty liver disease. Diabet Met 2006; 23:403-409.
109. Lin YC, Lo HM, Chen JD. Sonographic fatty liver, overweight and ischemic heart disease. World J Gastroenterol 2005; 11:4838-4842.
110. Balta S, Demirkol S, Ay SA, Kurt O, Unlu M, Celik T. Nonalcoholic fatty liver disease may be associated with coronary artery disease complexity. Angiology 2013; 64:639-640.
111. Agaç MT, Korkmaz L, Cavusoglu G, et al. Association between nonalcoholic fatty liver disease and coronary artery disease complexity in patients with acute coronary syndrome: A pilot study. Angiology 2013; 64:604-608.
112. Arslan U, Tü rkoʇ lu S, Balcioʇ lu S, Tavil Y, Karakan T, Cengel A. Association between nonalcoholic fatty liver disease and coronary artery disease. Coron Artery Dis 2007; 18:433-436.
113. Gensini GG. A meaningful scoring system for determining the severity of coronary heart disease. Am J Cardiol 1983; 51:606.
114. Açikel M, Sunay S, Koplay M, Gündoʇ du F, Karakelleoʇ lu S. Evaluation of ultra sonographic fatty liver and severity of coronary atherosclerosis, and obesity in patients undergoing coronary angiography. Anadolu Kardiyol Derg 2009; 9:273-279.
115. Sun L, Lü SZ. Association between nonalcoholic fatty liver disease and coronary artery disease severity. Chin Med J 2011; 124:867-872.